Product Information
RENVELA 800 MG TABLET is a brand product labeled by Genzyme Corporation, priced at $5.6852 per EA under NDC 58468013301. Its NADAC has been published 146 times since Nov 8, 2023.
FDA first approved this application on Oct 19, 2007.
The High Outlier badge above means this manufacturer's average price in the SEVELAMER CARBONATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
800 mg/1
Manufacturer
Genzyme CorporationNDC
58468013301
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
4/22/2026
Active Ingredients
SEVELAMER CARBONATEApproval Type
New Drug (NDA)
FDA Application
NDA022127FDA Approved
10/19/2007
On Market Since
8/12/2009
Pharmacological Classes
Price Statistics
The NADAC for RENVELA 800 MG TABLET has been published 146 times since Nov 8, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.6852 per EA |
|---|---|
| All-time high | $5.7781 (Dec 13, 2023) |
| All-time low | $5.6791 (Dec 20, 2023) |
| 52-week high | $5.7264 |
| 52-week low | $5.6852 |
| Median price | $5.7105 |
| Average price | $5.7075 |
| Largest weekly change | -1.7% (Dec 20, 2023) |
| Weeks tracked | 146 |
| Tracking since | Nov 8, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RENVELA 800 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RENVELA 800 MG TABLET, manufactured by Genzyme Corporation, is $5.6852 per EA (NDC 58468013301), effective Aug 19, 2026.
How has the price of RENVELA 800 MG TABLET changed over time?
Over the history we have for it, the NADAC for RENVELA 800 MG TABLET has held within roughly two percent of its current level. It has been tracked across 146 weekly CMS publications since Nov 8, 2023.
What are the highest and lowest recorded NADAC prices for RENVELA 800 MG TABLET?
Since Nov 8, 2023, the NADAC for RENVELA 800 MG TABLET has ranged from a low of $5.6791 (Dec 20, 2023) to a high of $5.7781 (Dec 13, 2023), with a median of $5.7105 per EA.
Are there cheaper alternatives to RENVELA 800 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SEVELAMER CARBONATE 800 MG TAB, is $0.2186 per EA — about 96% below RENVELA 800 MG TABLET.
Who manufactures RENVELA 800 MG TABLET?
RENVELA 800 MG TABLET (NDC 58468013301) is labeled by Genzyme Corporation, and CMS classifies it as a brand product.